This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 2
  • /
  • FDA approves sBLA for Takhzyro in pediatric patien...

FDA approves sBLA for Takhzyro in pediatric patients with hereditary angioedema.- Takeda

Read time: 1 mins
Published:5th Feb 2023

Takeda announced that the FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Takhzyro (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age.

Prior to approval, the only approved routine prophylaxis treatment options for children 6 to><12 years of age required dosing every three to four days, and children with hae 2 to><6 years of age had no approved prophylaxis treatment, making takhzyro the first prophylaxis treatment for this age group. the recommended dose is 150 mg 1 ml solution in a single-dose prefilled syringe every four weeks in patients 2 to><6 years of age and every two weeks in patients 6 to><12 years of age.></12></6></6></12></12>

The sBLA approval was supported by extrapolation of efficacy data from the HELP Study, a Phase III trial that included patients 12 to <18 years of age, and additional pharmacokinetic analyses showing similar drug exposures between adults and pediatric patients, as well as safety and pharmacodynamic data from the spring study, an open-label phase iii trial in 21 hae patients 2 to><12 years of age. the primary objectives of the spring study were the safety and pharmacokinetics of takhzyro. the most common treatment-related treatment emergent adverse events in the study were injection site pain (29%), injection site erythema (14%), injection site swelling (5%), administration site pain (5%) and injection site reaction (5%). the prevention of hae attacks was measured as a secondary objective. takhzyro reduced the rate of hae attacks in pediatric patients by a mean of 94.8% compared to baseline, from 1.84 attacks per month to 0.08 attacks during the 52-week treatment period (n="21)." the majority of patients (76.2%, n="16)" were attack-free with an average of 99.5% attack-free days. these efficacy results are from an open-label, non-controlled trial, and the study was not designed for statistical hypothesis testing. further confirmatory studies are required to draw any conclusions from these data.></12></18>

Condition: Hereditary Angio-Oedema
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.